Histotype
Pancreatic
| Parameter | Information |
|---|---|
| Strain | NUDE |
| Implant Type | Cells |
| Implant Location | SC - Axilla (High) |
| Time to Staging | 5 days |
| Time to Evaluation Size | 16.8 days |
| Td | 5.8 days |
The above parameters are from one study. For further information on this cell line and other parameters, including different strains, vendors, implant type and location and/or standards of care, please contact us.
Tumor Line
Human
Ref #
9024
Tumor models for pancreatic cancer
Learn more about this cell line in our scientific spotlights:
More than 90% of all pancreatic cancers are classified as ductal adenocarcinomas and, within the western-world, pancreatic cancer is the fourth leading cause of cancer related deaths. Prognosis with pancreatic cancer is extremely poor, with a 5-year relative survival rate of 5% and median survival of 3.5 months for patients with Stage III non-resectable tumors.1 Unfortunately, the incidence of pancreatic cancer has been on the rise while the 5-year survival rate has not changed. urgical resection is the only potentially curative therapy, but only 10% of patients are diagnosed early enough for this to be an option and most who are eligible for surgery ultimately relapse.
Modeling immuno-oncology in a humanized mouse
Learn more about this cell line in our scientific spotlights:
Immune deficient mice by design lack adaptive immunity which makes them an ideal host for supporting the transplantation and growth of human tumor cells. Preclinical xenograft models utilizing immune deficient mice are limited for the investigation of immunotherapies due to this lack of functional immune cells. This spotlight will highlight a method in which human T-lymphocytes cells can propagate within an immune compromised mouse and support tumor xenograft growth.